Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
Become a Member | Sign in
Home>News>This Article

BD launches New Safety Blood Collection Needle with Flashback Chamber

Published: Wednesday, October 03, 2012
Last Updated: Wednesday, October 03, 2012
Bookmark and Share
Intuitive, easy-to-use, single-handed activation device combines safety with added reassurance of flashback for the confidence of success.

BD (Becton, Dickinson and Company) has announces the launch of the new BD Vacutainer® Eclipse™ Signal™ Blood Collection Needle in Europe. The safety-engineered design with single-handed activation, integrated holder and a new flashback chamber offers healthcare workers immediate confirmation of venous access, whilst also reducing the potential for sharps injuries.

Blood collection is one of the most hazardous tasks healthcare workers perform. A European study[i] revealed that it is the procedure with the highest risk of needlestick injury compared to other clinical procedures. A single needlestick injury can expose a healthcare worker to one or more of 30 potentially dangerous blood-borne pathogens, including Hepatitis B, Hepatitis C and HIV.

Luis Fernandez-Inglesias, Vice President, BD Diagnostics, Preanalytical Systems Europe, says: “BD is committed to raising awareness of the risks faced by healthcare workers and educating and informing healthcare facilities on the precautions they can adopt, as well as developing safety-engineered devices for improving healthcare worker safety. The new BD Vacutainer® Eclipse™ Signal™ Blood Collection Needle represents a new level of confidence in safety-engineered devices for venous blood collection, designed specifically with healthcare workers’ safety in mind and ease of use.”

The BD Vacutainer® Eclipse™ Signal™ Blood Collection Needle allows immediate confirmation of venous access, which is indicated by the presence of blood in the flashback chamber, providing confidence during venepuncture. Other key ergonomic features which make venous blood collection simple and more comfortable, are the new anti-slip ridges and thumb pad for easy, single-handed activation of the safety shield. The blood droplet reduction system is designed to reduce blood droplet formation when the needle is removed from the vein, and the needle bevel and safety shield are aligned for easy identification of the needle position for blood collection. Full integration of the holder and needle reduces the risk of user-end sharps injuries and improves efficiency by reducing the number of steps in the blood collection process, with no compromise to patient care.

Mr Kor Kooi, PreAnalytical Manager at UMCG Hospital Groningen, one of the biggest University Hospitals in the Netherlands and the first site in Europe to order the BD Vacutainer® Eclipse™ Signal™, explains: "At Groningen, this new blood collection needle will provide an extra tool to use when carrying out these very important procedures.  The flashback chamber makes it much easier to determine if blood collection has been successful, and this invaluable feature also reduces the potential for patient discomfort."

It is estimated that one million sharps injuries occur in the European Union each year[iii], with more than 100,000 each year in the UK alone[iv]. The EU Directive on the prevention of sharps injuries in the hospital and healthcare sector[v] must be transposed into national law of all EU member states by 11 May 2013, placing an obligation on healthcare organisations “to achieve the safest possible working environment by preventing injuries to workers caused by all medical sharps”.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

BD Launches New Europe-wide Healthcare Worker Safety Website
Designed to help healthcare workers stay safe and minimise their risk of sharps injury.
Tuesday, June 12, 2012
Scientific News
Lucentis Effective for Proliferative Diabetic Retinopathy
NIH-funded clinical trial marks first major advance in therapy in 40 years.
Blocking the Transmission Of Malaria Parasites
Vaccine candidate administered for the first time in humans in a phase I clinical trial led by Oxford University’s Jenner Institute, with partners Imaxio and GSK.
First Therapy Appearing to Reverse Decline in Parkinson’s
An FDA-approved drug for leukemia improved cognition, motor skills and non-motor function in patients with Parkinson’s disease and Lewy body dementia in a small clinical trial, say researchers at Georgetown University Medical Center (GUMC).
Gene Therapy Staves Off Blindness from Retinitis Pigmentosa in Canine Model
NIH-funded study suggests therapeutic window may extend to later-stage disease.
Treatment for Rare Bleeding Disorder is Effective
Researchers in Manchester have demonstrated for the first time the relative safety and effectiveness of treatment, eltrombopag, in children with persistent or chronic immune thrombocytopenia (ITP), as part of an international duo of studies.
HIV Vaccine Human Trials Begin
Baltimore-based Institute has begun enrolling volunteers for initial phase 1 clinical trials.
New Therapy Reduces Symptoms of Inherited Enzyme Deficiency
A phase three clinical trial of a new enzyme replacement medication, sebelipase alfa, showed a reduction in multiple disease-related symptoms in children and adults with lysosomal acid lipase deficiency, an inherited enzyme deficiency that can result in scarring of the liver and high cholesterol.
Fixing Holes in the Heart Without Invasive Surgery
UV-light enabled catheter is a medical device which represents a major shift in how cardiac defects are repaired.
Atriva Therapeutics GmbH Develops Innovative Flu Drug
Highly effective against seasonal and pandemic influenza.
Study Removes Cancer Doubt for Multiple Sclerosis Drug
Researchers from Queen Mary University of London are calling on the medical community to reconsider developing a known drug to treat people with relapsing Multiple sclerosis after new evidence shows it does not increase the risk of cancer as previously thought.
Scroll Up
Scroll Down

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos